Drug Database
BE

betamethasone dipropionate (DFD01 / DFD 01 / Sernivo)

✓ Approved

Encore Dermatology, Inc. · Steroids · Steroids

What is betamethasone dipropionate?

betamethasone dipropionate is a steroids developed by Encore Dermatology, Inc.. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesDFD01, DFD 01, Sernivo
CompanyEncore Dermatology, Inc.
Drug ClassSteroids, Small Molecule
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Encore Dermatology, Inc.

Therapeutic Indications

betamethasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedObstetrics and gynecology2026-11-10

Hospital-Level Variation in Antenatal Corticosteroid Use for Late Preterm Births.

Clapp Mark A MA, Lee Dohyun D, Li Siguo S, James Kaitlyn E KE et al.

To determine whether and to what extent hospitals across the United States vary in their use of late preterm steroids. This was a retrospective cohort study of singleton births with known gestational ages identified in the Premier Healthcare Database from 2015 to 2022. The primary variable of interest was hospital-level adoption of antenatal corticosteroid use for late preterm singleton deliveries, calculated as the proportion of late preterm singleton births (34-36 completed weeks of gestation) with any betamethasone exposure during the same late preterm period. Hospital adoption was defined as the weighted average rate of steroid administration among late preterm births across the entire postperiod. Hospitals were ranked by their late preterm steroid adoption rates and categorized by quartile based on the empirical distribution. Temporal trends were assessed using annual hospital-level adoption rates and visualized using time series plots and distributional plots. A logistic regression model was constructed to identify hospital characteristics associated with being a highest-quartile adopter. The analysis cohort included 726 hospitals and 5,109,270 births, of which 309,837 (6.1%) were singleton late preterm births. Hospital steroid exposure rates ranged from 0% to 92% and were categorized into quartiles based on overall exposure rate, with cutoffs at 22.4%, 33.9%, and 45.1%. Median exposure rates increased progressively across quartiles, from 15.4% (IQR 10.0-18.9%) in the lowest-adopting hospitals (quartile 1) to 54.3% (IQR 49.1-61.0%) in the highest-adopting hospitals (quartile 4), with substantial within-quartile variation. In the multivariable model, urban location was a strong predictor of high adoption after adjustment (adjusted odds ratio [aOR] 2.03; 95% CI, 1.04-4.02, P=.04). Compared with Midwestern hospitals, Southern hospitals had significantly lower odds of being high adopters (aOR 0.32; 95% CI, 0.17-0.61, P<.001). Among clinical case mix variables, a higher proportion of late preterm births at 34 weeks of gestation was strongly associated with high adoption (aOR 2.39; 95% CI, 1.73-3.36, P<.001). After the publication of the ALPS (Antenatal Late Preterm Steroids) trial, the adoption of late preterm steroid use was heterogeneous among U.S. hospitals. These findings highlight the need for a more in-depth exploration of local factors that drive the adoption of evidence-based practices outside of observable hospital characteristics.

PMID 43008238
Read full article →
PubMedBMC anesthesiology2026-11-10

Erector spinae plane block in a patient with post-thoracotomy pain syndrome and intercostal neuralgia presenting with late-onset myoclonus: a case report.

Altunbag Yavuz Eda E, Seker Dincer Firat DF, Bayram Mustafa Gokhan MG, Yavuz Adil Ugur AU

Post-thoracotomy pain syndrome (PTPS) is a complex post-surgical chronic pain condition of the chest wall involving neuropathic, nociceptive, and nociplastic components, with intercostal neuralgia contributing in some cases. Intercostal neuralgia may occasionally present with motor manifestations, although such presentations have been infrequently described in the literature. Management of chronic PTPS remains challenging, particularly in cases refractory to medical therapy. The erector spinae plane block (ESPB) has been described as a regional analgesia technique in acute and chronic thoracic pain; however, its role in PTPS associated with motor symptoms has not been well defined. We report the case of a 60-year-old male who presented with severe chronic neuropathic pain in the left hemithorax seven years after undergoing a left posterolateral thoracotomy for lung mass excision. The pain was accompanied by late-onset myoclonus localized to the intercostal nerve distribution. Physical examination revealed hyperalgesia and high-frequency muscle spasms along the left T2-T6 dermatomes, with pain intensity rated as 8-9/10 on the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Imaging studies showed expected postsurgical changes of the chest wall, without evidence of additional structural pathology contributing to the patient's symptoms. Differential diagnoses, including herpes zoster infection and thoracotomy-related long thoracic and thoracodorsal nerve injuries, were considered less likely based on the clinical findings. With a preliminary diagnosis of PTPS and intercostal neuralgia, ultrasound-guided ESPB was performed at the T4 level using bupivacaine, lidocaine, and dexamethasone. Significant reduction in pain scores (NRS 1-2/10) and muscle spasm frequency was observed within 15 min. Due to recurrence of symptoms after 24 h, a second ESPB using bupivacaine and betamethasone was performed, followed by near-complete resolution of pain (NRS 0-1/10) and disappearance of muscle spasms. No complications were observed. The patient was discharged with oral neuropathic pain medication and referred for outpatient pain management follow-up. Telephone follow-up demonstrated significant symptom improvement for approximately three weeks. This case describes the use of ultrasound-guided ESPB in a patient with PTPS and intercostal neuralgia accompanied by late-onset myoclonic symptoms. ESPB was followed by rapid improvement in pain and reduction in involuntary muscle spasms. These observations may support further discussion of the possible role of ESPB in selected patients with PTPS, intercostal neuralgia, and associated motor manifestations.

PMID 43004169
Read full article →
PubMedBMC ophthalmology2026-11-06

Ocular safety of subconjunctival injection of tacrolimus in rabbits.

Hassanin Zakaria Z, Shama Ahmed A, Zakaria Nancy N, Mohalhal Islam A IA et al.

The main aim of this study was to evaluate the safety of subconjunctival injection of tacrolimus in rabbit eyes. Ten white New Zealand rabbits were included. A concentration of tacrolimus 0.03% was prepared for subconjunctival injection. Tacrolimus 0.03% was compounded by adding water for injection solution to 1,000 µg tacrolimus capsule (Prograf; Astellas Pharma Inc., Tokyo, Japan) to achieve 0.03% concentration. Prograf capsule inactive ingredients (excipients) inside the core included hypromellose, croscarmellose sodium, lactose monohydrate, and magnesium stearate. Tacrolimus 0.03% was injected subconjunctivally in one eye of each rabbit and water for injection solution was injected subconjunctivally into the contralateral eye. All rabbits underwent ocular examination in the 1st, 3rd, 10th and 30th day after injection. The following parameters were evaluated: tearing, hyperemia, conjunctival chemosis, and scleral necrosis/discoloration. The rabbits were sacrificed 30 days after injections and histopathological examination was performed on enucleated eyes. No tearing or scleral necrosis/discoloration was observed in either group. In the tacrolimus-injected eyes, conjunctival hyperemia and chemosis were minimal compared to the water-injected control eyes, where severe hyperemia was noted initially but improved over time. Histopathological examination revealed less lymphocytic infiltration and better-preserved scleral and corneal structures in the tacrolimus group. Subconjunctival tacrolimus demonstrated a promising safety profile. No serious adverse events were noted clinically or pathologically.

PMID 42989202
Read full article →
PubMedJournal of pharmaceutical sciences2026-11-05

Optical coherence tomography as a process analytical technology for oral film formulations.

Uth Leonie-Lara Dorothea LD, Wolfgang Matthias M, Klinken-Uth Stefan S, Khinast Johannes J et al.

In oral film manufacturing, the dose of the active pharmaceutical ingredient is set by cutting the cast film into portions of defined area, which makes film thickness a critical quality attribute and an attractive target for calibration-free in-process measurement. This study evaluated Optical Coherence Tomography (OCT) to monitor film thickness of oral films along the offline-to-inline continuum. A galvanometer-scanning spectral-domain OCT system, acquiring full two-dimensional cross-sections, was applied offline to cast films and inline above the moving, dried film of a continuous coating line. An OSeeT Pharma 1D sensor, which acquires depth profiles at a fixed lateral position and evaluates the interfaces within the instrument, was operated on a custom-built conveying bench reproducing continuous film movement. Offline, OCT resolved internal defects, including air bubbles, insoluble inclusions and the interlayer boundary of bilayer films. Preliminary observations further indicated its potential to detect storage-related microstructural changes. OCT consistently yielded higher thickness values than a manually operated micrometer screw, with potential contributing factors, including film compression during contact measurement and the assumption of a constant refractive index, being discussed. Inline, thickness variations induced by deliberate variation of pump rate, coating knife height and liner speed were resolved for three different polymeric film formers, with thickness values extracted by post-processing of the recorded cross-sections, although evaluable frames were lost wherever the moving film left the set focal range. The OSeeT sensor returned stable thickness, roughness and homogeneity along the entire film length and reproduced the same systematic offset against the micrometer screw reference, delivering these values continuously and without post-processing. Structural information therefore remains available alongside continuous monitoring if the acquisition is configured to retain it. The main obstacles to the use of OCT as an inline Process Analytical Technology in continuous oral film manufacturing therefore lie in system integration, i.e. mechanical film guidance, automated onboard evaluation and image retention, rather than in the optical performance of the instruments.

PMID 42988115
Read full article →
PubMedDrug delivery and translational research2026-11-04

Development and evaluation of a microneedle-assisted transdermal delivery system for compound betamethasone in atopic dermatitis.

Wang Si-Ning SN, Qiao Xiaojing X, Du Fangzhi F, Chen Jing J et al.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunctio​n and immune dysregulation, which may influence topical drug penetration and therapeutic efficacy. This study evaluated a microneedle-assisted approach to enhance the cutaneous delivery of compound betamethasone in AD. Franz diffusion cell experiments demonstrated 3.29-fold and 4.67-fold increases in the 24-h cumulative permeation of betamethasone dipropionate (BDP) and betamethasone sodium phosphate (BSP), respectively, compared with passive application. In vivo fluorescence imaging showed greater penetration depth of fluorescein sodium following microneedle treatment, while histological examination revealed transient epidermal disruption. In a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model, the combined treatment was associated with reduced epidermal thickening, mast cell accumulation, and serum IgE and IL-13 levels. In a pilot split-body clinical study involving 28 participants with mild-to-moderate AD, the microneedle + compound betamethasone-treated side showed greater improvements in Scoring Atopic Dermatitis (SCORAD) intensity and numeric rating scale (NRS) pruritus scores than the contralateral microneedle + saline control side after 7 days. No serious adverse events were observed during the study period. These findings demonstrate enhanced cutaneous permeation of compound betamethasone following microneedle-assisted application and provide preliminary evidence of therapeutic activity and short-term tolerability in AD.

PMID 42981018
Read full article →
PubMedPediatric blood & cancer2026-11-04

Beclomethasone Dipropionate Powder via Nasojejunal Tube as a Practical Treatment Option for a Child Unable to Swallow Enteric-Coated Capsules: A Case Report.

Yokokawa Yuichi Y, Okumura Shunichi S, Yuza Yuki Y

PMID 42980078
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about betamethasone dipropionate